Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease.

Polydoro M, de Calignon A, Suárez-Calvet M, Sanchez L, Kay KR, Nicholls SB, Roe AD, Pitstick R, Carlson GA, Gómez-Isla T, Spires-Jones TL, Hyman BT.

J Neurosci. 2013 Aug 14;33(33):13300-11. doi: 10.1523/JNEUROSCI.0881-13.2013.

2.

Propagation of tau pathology in a model of early Alzheimer's disease.

de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT.

Neuron. 2012 Feb 23;73(4):685-97. doi: 10.1016/j.neuron.2011.11.033. Erratum in: Neuron. 2012 Oct 18;76(2):461.

3.

Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease.

Pooler AM, Polydoro M, Maury EA, Nicholls SB, Reddy SM, Wegmann S, William C, Saqran L, Cagsal-Getkin O, Pitstick R, Beier DR, Carlson GA, Spires-Jones TL, Hyman BT.

Acta Neuropathol Commun. 2015 Mar 24;3:14. doi: 10.1186/s40478-015-0199-x.

4.

Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice.

Ishihara T, Zhang B, Higuchi M, Yoshiyama Y, Trojanowski JQ, Lee VM.

Am J Pathol. 2001 Feb;158(2):555-62.

5.

Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model.

Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, Pitstick R, Carlson GA, Staley KJ, Spires-Jones TL, Hyman BT.

Acta Neuropathol. 2014 Feb;127(2):257-70. doi: 10.1007/s00401-013-1215-5. Epub 2013 Nov 24.

6.

Tau-amyloid interactions in the rTgTauEC model of early Alzheimer's disease suggest amyloid-induced disruption of axonal projections and exacerbated axonal pathology.

Pooler AM, Polydoro M, Wegmann SK, Pitstick R, Kay KR, Sanchez L, Carlson GA, Gomez-Isla T, Albers MW, Spires-Jones TL, Hyman BT.

J Comp Neurol. 2013 Dec 15;521(18):4236-48. doi: 10.1002/cne.23411.

7.
8.

A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.

Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM.

Am J Pathol. 2010 Oct;177(4):1977-88. doi: 10.2353/ajpath.2010.100346. Epub 2010 Aug 27.

9.

Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.

Umeda T, Maekawa S, Kimura T, Takashima A, Tomiyama T, Mori H.

Acta Neuropathol. 2014 May;127(5):685-98. doi: 10.1007/s00401-014-1259-1. Epub 2014 Feb 15.

PMID:
24531886
10.

Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology.

Leroy K, Ando K, Héraud C, Yilmaz Z, Authelet M, Boeynaems JM, Buée L, De Decker R, Brion JP.

J Alzheimers Dis. 2010;19(2):705-19. doi: 10.3233/JAD-2010-1276.

PMID:
20110614
11.

[Significance of tau in the development of Alzheimer's disease].

Takashima A.

Brain Nerve. 2010 Jul;62(7):701-8. Review. Japanese.

PMID:
20675874
12.

Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy.

Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM.

J Neurosci. 2013 Jan 16;33(3):1024-37. doi: 10.1523/JNEUROSCI.2642-12.2013.

13.

A rapid gene delivery-based mouse model for early-stage Alzheimer disease-type tauopathy.

Siman R, Lin YG, Malthankar-Phatak G, Dong Y.

J Neuropathol Exp Neurol. 2013 Nov;72(11):1062-71. doi: 10.1097/NEN.0000000000000006.

14.

14-3-3 protein beta isoform is associated with 3-repeat tau neurofibrillary tangles in Alzheimer's disease.

Sugimori K, Kobayashi K, Kitamura T, Sudo S, Koshino Y.

Psychiatry Clin Neurosci. 2007 Apr;61(2):159-67.

15.

Tau aggregation is a therapeutic target for Alzheimer's disease.

Takashima A.

Curr Alzheimer Res. 2010 Dec;7(8):665-9. Review.

PMID:
20678070
16.

Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau.

Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, Yoshiike Y, Sahara N, Takashima A.

EMBO J. 2007 Dec 12;26(24):5143-52. Epub 2007 Nov 15.

17.

[Drug development for tauopathy and Alzheimer's disease].

Takashima A.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):177-80. Review. Japanese.

PMID:
20857696
18.

Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease.

Ke YD, Delerue F, Gladbach A, Götz J, Ittner LM.

PLoS One. 2009 Nov 19;4(11):e7917. doi: 10.1371/journal.pone.0007917.

19.

Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.

Koson P, Zilka N, Kovac A, Kovacech B, Korenova M, Filipcik P, Novak M.

Eur J Neurosci. 2008 Jul;28(2):239-46. doi: 10.1111/j.1460-9568.2008.06329.x.

PMID:
18702695
20.

Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo.

Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskiy N, Andermann ML, Spires-Jones TL, Bacskai BJ, Hyman BT.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):510-4. doi: 10.1073/pnas.1318807111. Epub 2013 Dec 24.

Supplemental Content

Support Center